01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
glp-1 drugs retatrutide Retatrutide, a GIP, and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide: The Future of GLP-1
Description
Nakade, Y., Tsukamoto, K., Pappas, T
The most common sleep-related effects include mild insomnia during dose escalation (affecting roughly 8% of users) and occasional vivid dreams, both of which typically resolve within 4 to 6 weeks
Not everybody responds in exactly the same way to these drugs. Most patients taking GLP-1 drugs lose an average of 10-15% of their body weight in a year
However, patients treated with liraglutide suffered numerically more serious adverse cardiac events than those on placebo (12 vs
